Pier Capital’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.25M Buy
+555,079
New +$3.84M 0.62% 78
2025
Q1
– Sell
-1,127,773
Closed -$6.15M – 123
2024
Q4
$6.15M Buy
1,127,773
+651,921
+137% +$4.19M 0.88% 71
2024
Q3
$3.95M Sell
475,852
-2,503
-0.5% -$21.6K 0.56% 93
2024
Q2
$3.43M Sell
478,355
-27,940
-6% -$241K 0.51% 90
2024
Q1
$4.39M Buy
506,295
+219,446
+77% +$1.48M 0.6% 77
2023
Q4
$1.88M Sell
286,849
-3,714
-1% -$24K 0.27% 93
2023
Q3
$2.91M Sell
290,563
-5,487
-2% -$60.3K 0.47% 88
2023
Q2
$3.68M Sell
296,050
-5,298
-2% -$71.5K 0.53% 90
2023
Q1
$4.22M Buy
301,348
+29,193
+11% +$419K 0.64% 78
2022
Q4
$3.89M Buy
272,155
+254,314
+1,425% +$4M 0.64% 76
2022
Q3
$455K Sell
17,841
-13,785
-44% -$346K 0.08% 96
2022
Q2
$898K Buy
31,626
+12,244
+63% +$388K 0.15% 90
2022
Q1
$684K Buy
19,382
+9,014
+87% +$302K 0.09% 98
2021
Q4
$434K Buy
+10,368
New +$420K 0.05% 107

Other funds holding MRVI

Pier Capital's MRVI Position: Q3 2026 in Review

Pier Capital opened a new position in Maravai LifeSciences (MRVI) in Q3 2026: 555,079 shares worth $4.25M. The stake represents 0.62% of the portfolio and ranks #78 among its holdings. This is a return to the name: Pier Capital previously reported a position in MRVI as recently as Q4 2024.

Pier Capital first reported a position in MRVI in Q4 2021 and has held it in 14 quarters since. The position peaked at $6.15M in Q4 2024. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

  • Pier Capital held 555,079 shares of Maravai LifeSciences worth $4.25M as of Q3 2026.
  • Maravai LifeSciences was a new Pier Capital position in Q3 2026.
  • Maravai LifeSciences made up 0.62% of Pier Capital's portfolio in Q3 2026, its #78 holding.
  • Pier Capital first reported a position in Maravai LifeSciences in Q4 2021 and has held it in 14 quarters since.
  • Pier Capital's Maravai LifeSciences position peaked at $6.15M in Q4 2024.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on Pier Capital's 13F filing for Q3 2026, filed 13 Nov 2026.